The AI Revolution in Drug Discovery: Transforming Healthcare

 By: Aidan McCartin


            My world was destroyed as a young child when I witnessed my uncle go on an exhausting battle of pancreatic cancer. Each time I looked at his frail body, the toll the sickness had taken became clearer. As a kid, I couldn't help but think, "Why can't they find a cure?" "Are the doctors doing everything possible?" I desperately sought someone or something to blame for my pain. With the passage of time and maturation, I became aware of the limitations of the medical industry at the time. Nonetheless, optimism stayed within me, hoping that one day, due to breakthroughs in medicine and technology, no one else would have to go through the same heartbreak that I had.

In recent decades, Artificial intelligence has permeated virtually every aspect of our lives, and its influence is only set to expand further. According to GlobalData, the AI market will be worth $909 billion by 2030, demonstrating the technology’s widespread use and growing potential. One area where AI is making significant strides is drug discovery and development, offering the promise of revolutionizing patient experiences and outcomes. The use of artificial intelligence in this field has the potential to shorten the time and lower the cost of bringing new pharmaceuticals to market, with a particular emphasis on solving unmet medical needs such as uncommon diseases and novel antibiotics.

 Recently, advances in computational technology have reshaped the field of drug discovery. Adoption of in silico approaches, in which research is carried out using computer simulations, has resulted in improved traditional drug development practices. These computational technologies have the potential to speed up drug development while reducing costs and timelines. Despite these advancements, the drug development process remains loaded with problems. Only 10% of prospective drug candidates progress from preclinical to clinical trials. The low success rates and resulting financial burden have fueled a search for alternate ways, resulting in the introduction of AI in drug discovery.

AI has enormous potential for enhancing in silico methods by rapidly processing and exploring the vast chemical space, made possible by the exponential growth of biomedical data. Researchers have gained a better grasp of the core mechanisms underlying diseases due to AI models trained on massive amounts of genomic data, health records, medical imaging, and patient information. By mapping illness pathways and detecting protein-drug interactions, AI has led to the discovery of new proteins and genes that can be targeted to treat diseases. Furthermore, AI can predict the three-dimensional structures of pharmaceutical drugs using databases such as DeepMind’s AlphaFold, speeding up the design of appropriate treatments and medications.

AI does not end at drug recognition. It is also important in candidate drug prioritization, ranking compounds for future evaluation. Furthermore, AI algorithms have shown the ability to reduce the traditional four-to-five-year exploratory research phase to less than a year. This time and cost savings are especially significant for medical conditions with restricted treatment alternatives, such as rare diseases.

In recent years, there has been a rise of interest in the use of AI in drug discovery, resulting in the formation of multiple firms, partnerships, and record levels of investment in this industry. Significant milestones have occurred in 2023, revealing AI’s transformational potential. In January, for example, AbSci made a breakthrough by utilizing generative AI to develop and validate de novo antibodies in silico. This innovative approach has the potential to drastically shorten the time it takes to transfer new medication leads into clinical trials. Similarly, Insilico Medicine was granted orphan drug designation by the FDA in February 2023 for a small molecule inhibitor treatment designed through their generative AI platform, Pharma.AI.

Even though there is significant progress in the application of AI in drug discovery, the majority of AI-developed medications are still in the preclinical or discovery stages. It could more than likely be years before an AI-based medicine receives regulatory approval. Concerns about data quality, medicine safety, effectiveness, community education, and intellectual property rights are among the many obstacles to widespread adoption. Nonetheless, AI’s early impact on traditional drug discovery techniques can be seen. AI has the ability to speed and reduce the costs of conducting expensive tests when integrated into traditional methods, providing massive benefits for patients, medical practitioners, and the pharmaceutical industry.

Despite these advancements, it is important to remember that fully realizing AI’s potential in drug discovery is a difficult process. These include issues with data quality and ethics, regulatory approval challenges and the need for more scientific education and collaboration. As these challenges are overcome, we may expect that AI will play a pivotal role in expediting drug discovery, reducing costs, and ultimately improving patient outcomes.

To summarize, AI’s breakthrough into drug research is a stunning demonstration to technology’s possibilities in altering healthcare. We can look forward to a future where AI-driven innovations help address some of the most pressing medical challenges and bring hope to patients, like my uncle, with unmet medical needs, thanks to ongoing research and development, regulatory changes, and increased acceptance of AI in the scientific and medical communities.

 

 

Work Cited

Healthcare, GlobalData. “Ai Essential for Drug Development and Discovery.” Pharmaceutical Technology, 10 Aug. 2023.

Paul, Debleena, et al. “Artificial Intelligence in Drug Discovery and Development.” Drug Discovery Today, U.S. National Library of Medicine, Jan. 2021.


Comments

Post a Comment

Popular posts from this blog

Molecules, Models, and Magic: The Exciting World of Computational Chemistry

Vrinda Modi I often spend time in a little cubicle in McLean in the freezing corporate cold wrapped in a blanket in the Hoboken summers sipping on free coffee from the office above. It almost always tastes like chalk, but the routine is so embedded in me. Hence, this is the perfect opportunity to talk a little more about my research in computational chemistry here at Stevens and the advances I expect in the next few years. This field excites me because it bridges my interest in chemistry with modern computing techniques, a powerful tool for advancing our understanding of chemical reactions and molecular interactions. This means we are a dry lab – running simulations on computers. No chemicals, no PPE, just models and algorithms. But why does computational chemistry exist in the first place, especially when chemistry is so rooted in physical matter? The answer is efficiency. Modeling molecules on a computer saves us from ordering chemicals, waiting for deliveries (a delay in chemistry t...
Read more

Scaling the Potential of Vertical Farming Going into 2025 and Beyond

Image
  Matthew P Kearney Scaling the Potential of Vertical Farming Going into 2025 and Beyond      Vertical farming may seem like something out of a futuristic movie, but they are very real in today’s agricultural industry. Vertical farming may promote a stronger relationship between urbanization and sustainable crop production. Based on recent innovations across agriculture and technology, vertical farming has the potential to revolutionize our current farming system. Through the development of vertical farming-based production lines, cities and otherwise unfarmable areas can be provided with fresh, local, and pesticide-free produce. Vertical farming and other adaptations of agriculture are not new ideas, but instead a historic and human process.      These technologies are ready to meaningfully address global food security through the technological and computational advancements in agriculture. Vertical farming has a promising future, which becomes a case...
Read more

Knot Your Average Problem: How do Tongue Ties Impact Oral Myofunctional Health?

Image
  Hadia Hussain      Knot Your Average Problem: How do Tongue Ties Impact Oral Myofunctional Health? Sitting in the nursery of the dental office where I worked, I reviewed Baby V’s medical history and reports from the Emergency Department at Jersey City Medical Center. I found it odd that, despite multiple visits and clear signs of malnutrition, no physician had been able to diagnose the cause. Baby V, at a low weight of 12 pounds was struggling with difficulty nursing and bottle feeding, excessive gassiness, colic, clicking sounds when feeding, milk dribbling out of the mouth, and mouth breathing—but doctors had dismissed these signs, labeling him as "healthy."  It didn’t make sense as his low weight raised serious concerns.  According to Pediatric specialists Jenny Olson, DNP, and Sarha DeVrieze, ARNP, at the UnityPoint Clinic, a 9-month-old baby boy should weigh anywhere in between the range of 17 to 25 pounds. Baby V's situation was clearly a ...
Read more